 COPENHAGEN, Denmark, Sept. 29, 2021 GLOBE NEWSWIRE -- Ascendis Pharma AS Nasdaq: ASND, a biopharmaceutical company that utilizes its innovative TransConTM technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced that its Board of Directors has authorized the Company to repurchase up to 25 million of the Companys American Depositary Shares ADS the Share Repurchase Program, each of which represents one ordinary share of Ascendis Pharma AS. The program will be executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations. 